Element5
Element5 is a healthtech company specializing in intelligent automation for post-acute care operations. Their platform leverages AI and robotic process automation to streamline eligibility verification, authorization processing, and revenue cycle management, significantly reducing administrative burdens and accelerating patient care. Their flagship product, Neos, deploys AI agents across the patient financial journey to optimize outcomes and create staff capacity. Trusted by industry leaders, Element5 automates over 30 million transactions annually, offering a fully managed solution that integrates with existing healthcare systems to improve efficiency and financial performance in post-acute care settings.
Element5
Element5 is a healthtech company specializing in intelligent automation for post-acute care operations. Their platform leverages AI and robotic process automation to streamline eligibility verification, authorization processing, and revenue cycle management, significantly reducing administrative burdens and accelerating patient care. Their flagship product, Neos, deploys AI agents across the patient financial journey to optimize outcomes and create staff capacity. Trusted by industry leaders, Element5 automates over 30 million transactions annually, offering a fully managed solution that integrates with existing healthcare systems to improve efficiency and financial performance in post-acute care settings.
TL;DR
Sector: Healthtech — AI & RPA for post-acute care
Flagship product: Neos — agentic automation across patient financial journey
Scale: Automates >30M transactions annually; 121K transactions/day
Funding: $48.5M total; Series B reported May 3, 2022
Headquarters: San Jose, California
Company Overview
Problem Domain
Post-acute care administrative operations (revenue cycle management, audits/compliance, eligibility and authorization workflows).
Founded
2019
Industry
Healthcare / Healthtech
Tech Stack
Funding Track Record
15000000.00
Company announced a $15M Series A led by Insight Partners
Most recent round reported on May 3, 2022
Investor Signal
“Insight Partners participation (led Series A)”